Programming

Joint Hypertension 2018 Scientific Sessions

AHA Council on Hypertension | AHA Council on Kidney in Cardiovascular Disease
American Society of Hypertension

September 6–9, 2018
Hyatt Regency Chicago | Chicago, Ill.
Registration Information
Take advantage of Early Registration prices through July 6, 2018.


See more Registration and Housing information.
Abstract Submission
NEW Late-Breaking Abstracts close Mon., June 4, 11:59 p.m. CT


See Late-Breaking Abstract Categories & Submission Guidelines (PDF)

Schedule

Download a printable copy of this Schedule-at-a-glance (PDF) or click on each day to see details below:

Click on a day/date to expand or collapse

#Hypertension18 Thursday, Sept. 6
TIMEACTIVITY
7:00 – 7:45 a.m.Coffee & Exhbits
7:45 – 8:00 a.m.President's Welcome
Ivor Benjamin, MD, FAHA
8:00 – 10:00 a.m.Session 1: Opening Remarks and Lectures
Highlights of the New Hypertension Guidelines – Jan Basile, MD, F.A.S.H.
Implementation of the New Hypertension Guidelines – Brent Egan, MD
Clinical Hypertension Research: Where Do We Go From Here? – Suzanne Oparil, MD
Recent Advances and Future Directions in Basic Research – David Ellison, MD
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:10 a.m.Session 2: Lifestyle Modifications and Impact on BP
Optimizing Cardiometabolic Health – Robert J. Chilton, MD
The Anti-Aging Effects of Aerobic Exercise on Systemic Arteries – Hirofumi Tanaka, PhD
11:10 – 12:00 p.m.Obesity and Cardiovascular Disease
Obesity Paradox in Hypertension: Should the SNS Be a Target to Improve Cardiometabolic Risk? – Elisabeth Lambert. PhD, Swineburne University of Technology
Cardiovascular Disease and Obesity: Recent Advances and Future Directions – John Hall, PhD
12:00 – 1:30 p.m.Lunch on Your Own
TAC Mentoring Lunch
1:30 – 3:00 p.m.Concurrent Session 4
A
Obesity, Diabetes & Metabolic Syndrome
BCardiac Hypertrophy and Dysfunction
CPregnancy and Preeclampsia I
1:30 – 3:00 p.m.Concurrent Session 4
D
Clinical Practice Clinical Science Track – Aldosterone and Primary Aldosteronism in Hypertension
The Potassium, Aldosterone, Blood Pressure Axis
The New Genetics of Aldosteronism
Screening and Diagnosis of Aldosteronism 2018
Hyperaldosteronism as a Cause of Resistant Hypertension
Q&A
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 5
A
– Inflammation, Immunity & Cytokines with 30-minute Mini Review Session
5:00-5:30pm
Recent Advances in our Understanding of Inflammation, Immunity & Cytokines – Ernesto L. Schiffrin, MD, PhD
B - Cerebrovascular Disease, Stroke, and Aging
C
– Renin Angiotensin System I with 30-minute Mini Review Session
3:30-4:00pm
Recent Advances in our Understanding of the Renin Angiotensin System – Jan Danser, PhD
3:30 – 5:30 p.m.Concurrent Session 5
D – Clinical Practice Clinical Science Track: Managing Hypertension in At-Risk-Populations

Goals of Hypertension Management in Patients with Chronic Kidney Disease
Strategies for Control of Hypertension in Renal Transplant Recipients
State-of-the-Art on Management of Pregnancy-Associated Hypertension
Managing Cardiovascular Complications in Patients Treated with VEGF Inhibitors and Other Chemotherapeutic Agents
Treating Post Stroke Hypertension: Thresholds and Goals
Panel Discussion
6:00 – 7:00 p.m.POSTER SESSION I
Trainee Onsite Poster Competition with Reception

#Hypertension18 Friday, Sept. 7
TIMEACTIVITY
7:00 – 8:00 a.m.Coffee and Exhibits
8:00 – 9:00 a.m.Session 6: Debate – Renal Denervation: Is There a Role in Essential Hypertension?
Pro: Ray Townsend, MD
Con: George Bakris, MD
9:00 – 10:00 a.m.Session 7: Hot Topics in Hypertension
Epigenetic Determinants of Cardiovascular Gene Expression: Vascular Endothelium – Phil Marsden, MD
Sex Differences in Mechanisms of Hypertension Association with Obesity – Eric Belin de Chantemele, D.SC
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:15 a.m.Session 8: Hot Topics in Hypertension
The Progression from Hypertension to Congestive Heart Failure in Patients: How Do We Stop It? – Daniel Levy, MD
SGLT Inhibitors for Hypertension, Renal and Cardiovascular Disease – Christopher Wilcox, PhD 
11:15 – 12:00 p.m.Session 9: Blood Pressure and Neurocognition
Will the New Guidelines Effect Cognition in Adults? – Jeff Williamson, MD
BP and Cognition in Children and Adolescents – Marc Lande, MD, MPH
12:00 – 1:30 p.m.Lunch on Your Own
12:00 – 1:30 p.m.Jansen Product Theater; Diabetes
Lunch Provided
1:30 – 3:00 p.m.POSTER SESSION II
1:30 – 3:00 p.m.Session 10: Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines, Part 1
Welcome and Introduction to Primary Care Track: Goals and Objectives – Jan Basile, MD
What do the 2017 ACC/AHA Guidelines Actually Say? – Sandra Taler, MD
Understanding the Data that Drove the 2017 ACC/AHA Guidelines – Paul Muntnter, PhD
The Difference Between Blood Pressure Targets and Performance Measures: Brief Explanation of the Epidemiology of Achieved Blood Pressure – Brent Egan, MD
The American College of Physicians (ACP) and American Academy of Family Practice (AAFP) Perspective – Marie Brown, MD
Q&A
3:00 – 3:30 p.m.Refreshment Break
3:30 – 4:00 p.m.Arthur C. Corcoran Memorial Lecture
4:00 – 5:30 p.m.Concurrent Session 11
A
– Gender Differences and Sex Hormones
B – Hypertension Early Career Oral Awards Session
C – Chronic Kidney Disease
3:30 – 5:30 p.m.Concurrent Session 11: D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 2: Areas of Controversy
Blood Pressure Goals in Diabetes and Chronic Kidney Disease – George Bakris, MD
The Older Patient with Hypertension – Matthew Sorrentino, MD
Treating Hypertension in Low-Risk Individuals: How Long Do We Hold Off on Pharmacologic Treatment? – Stephen Williams, MD
Can't We All Just Get Along? Finding Consensus Among Guidelines and Statements – Michael Bloch, MD
Case Based Discussion Panel on Areas of Controversy in the Guidelines
Q&A
5:30 – 5:45 p.m.Refreshment Break
5:45 – 6:45 p.m.Session 12: Awards Session
Mid-Career Award
Harry Goldblatt Award
British Hypertension Society Young Investigator Award
High Blood Pressure Research Council of Australia Award
7:00 – 11:00 p.m.Trainee Advocacy Mixer

Hypertension18 Saturday Sept 8
TIMEACTIVITY
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 8:00 a.m.Donald Seldin Award Lecture
8:00 – 9:30 a.m.Concurrent Session 13
A – Vascular Biology and Dysfunction
B – Renal Hemodynamics and Tubular Transport
C – Hypertension Journal Case Studies
7:30 – 9:30 a.m.Concurrent Session 13:
D – Primary Care Track: Emerging Issues in Hypertension Management

How Do Environmental Factors Effect Blood Pressure? – Robert E Brook, MD
Treatment of Hypertension in the Women Considering Conception – Angela Brown, MD
Remote Monitoring and Patient Self-Management - Is it the Future of BP Management? – Debbie L Cohen, MD
Management of Hyper-and-Hypo-Kalemia in Treated Hypertensive Patients – Matthew Weir, MD
Surgical and Percutaneous Interventions in Management of Hypertension – Ray Townsend, MD
Q&A
9:30 – 10:00 a.m.Refreshment Break
10:00 – 10:30 a.m.Harriet Dustan Award Lecture
10:30 – 12:00 p.m.Concurrent Session 14
A – Blood Pressure Monitoring, Control and Adherence to Treatment
B – Clinical Trials, Antihypertensive Drugs and Pharmacology
C – Neurogenic Mechanisms I
10:00 – 12:00 p.m.Concurrent Session 14
D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 3: Special Situations
Determining Adequacy of BP Control: Using Appropriate Technique and Integrating In and Out of Office Measurements – Daichi Shimbo, MD
Management of Resistant Hypertension: Have We Learned Anything New? – David Calhoun, MD
Implementation of Pediatric Guidelines for Hypertension Management – Joshua Samuels, MD, MPH
Q&A
Case 1: Presented by Local PCP
Case 2: Presented by Local PCP
12:00 – 1:30 p.m.Awards Luncheon and Business MeetingTickets Required
1:30 – 3:00 p.m.POSTER SESSION III
1:30 – 3:00 p.m.Clinical Practice Clinical Science Track: Taking Hypertension into the Community
Part One: The Barbershop
Cluster Randomized Trials of Blood Pressure Reductions in Black Barbershops
Q&A
Part Two: Telemonitoring, Self-Monitoring, and BP Control
The Role of Telemonitoring in Improving BP Control
Telemonitoring vs. Self-Monitoring in BP Control: Does it Make a Difference?
Q&A
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 16
A – Asian Pacific Symposium on Cardiovascular Research
B – Salt and Hypertension
C – Aldosterone, Receptors and Other Hormones
3:30 – 5:30 p.m.Concurrent Session 16
D – Clinical Practice Clinical Science Track: AHA Council on Hypertension/ESC Council on Hypertension Joint Session
ESC/ESH Guideline on Hypertension 2018
The Canadian Guideline: Differences and Similarities to the European Guideline
US, European and Canadian Guidelines: What is the Clinician to Do?
Device-Based Treatment for Hypertension: Who, When and How?
5:45 – 6:30 p.m.Session 17
The Excellence in Hypertension Research Award
7:00 – 7:30 p.m.Social Hour
Cash Bar – Dinner ticket required for entrance
7:30 – 10:30 p.m.Annual Business Meeting and Award DinnerDinner ticket required
Join us in celebrating and recognizing all of our Awardees, including the recipients of the Excellence in Hypertension Research Award.

Hypertension18 Sunday, Sept 9
TIMEACTIVITY
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 8:00 a.m.Dahl Award Lecture
8:00 – 9:30 a.m.Concurrent Session 18
A
– Neurogenic Mechanisms II
B – Vascular Stiffness
C – Epidemiology, Genetics and Epigenetics
8:00 – 9:20 a.m.Concurrent Session 18
D – Clinical Practice Clinical Science Track: Getting It Done: Practical Ways to Improve Blood Pressure Control, Part 1
Introduction
Secrets to Sustain a Low-Sodium DASH Diet In Your Patient
How to Get Your Patients to Exercise
Practical Pearls in Using Weight-loss Medications in Patients with Hypertension
Calculating Risk Using the Cardiovascular Risk Estimator
Panel Discussion
9:30 – 10:00 a.m.Refreshment Break (for Concurrent Session 18 A-B-C)
9:20 – 9:40 a.m.Refreshment Break (for Concurrent Session 18 D)
10:00 – 11:00 a.m.Concurrent Session 19
A – Oxidative Stress, Nitric Oxide, Endothelin, and Other Endothelial Factors
B – Inflammation, Immunity and Cytokines II
C – Pregnancy and Preeclampsia II
9:40 – 11:00 a.m.Concurrent Session 19
D – Clinical Practice Clinical Science Track: Getting It Done: Practical Ways to Improve Blood Pressure Control, Part 2
Getting Ambulatory Blood Pressure Monitoring Reimbursed
Which Device Should We Use for Office BP Measurement
Promoting Accurate Home Blood Pressure Monitoring
Team-based Approach to Blood Pressure Telemonitoring
Panel Discussion / Q&A
11:00 a.m.Meeting Adjourns

About This Meeting

AHA’s Hypertension 2018 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

The planned agenda includes 18 sessions during 3½ days, with more than 500 presentations focused on recent advances in hypertension research including oral and poster presentations selected from abstracts submitted by clinical and basic researchers as well as the Primary Care and Clinical Practice Clinical Science Tracks for Clinicians.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
     
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
     
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
     
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
     
  5. Describe new and emerging strategies for treating resistant hypertension.
     
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.